Full Text @ Edgewood Coll

Exosome-Based Detection of EGFR T790M in Plasma from Non–Small Cell Lung Cancer Patients

E Castellanos-Rizaldos, DG Grimm, V Tadigotla… - Clinical cancer …, 2018 - AACR
Abstract Purpose: About 60% of non–small cell lung cancer (NSCLC) patients develop
resistance to targeted epidermal growth factor receptor (EGFR) inhibitor therapy through the …
被引用次数：192 相关文章
Full Text @ Edgewood Coll

[引用][C] Exosome-Based Detection of EGFR T790M in Plasma from Non–Small Cell Lung Cancer Patients

E Castellanos-Rizaldos, DG Grimm… - Clinical Cancer …, 2018 - mediatum.ub.tum.de
mediaTUM - Medien- und Publikationsserver mediaTUM Universitätsbibliothek Technische
Universität München Logo Benutzer: Gast Login de en mediaTUM Gesamtbestand …
[PDF] researchgate.net

[PDF][PDF] Exosome-based Detection of EGFR T790M in Plasma from Non-Small Cell Lung Cancer Patients

E Castellanos-Rizaldos, DG Grimm, V Tadigotla… - researchgate.net
Abstract Purpose: About 60% of non-small cell lung cancer (NSCLC) patients develop
resistance to targeted epidermal growth factor receptor (EGFR) inhibitor therapy through the …
Full Text @ Edgewood Coll

Exosome-Based Detection of EGFR T790M in Plasma from Non-Small Cell Lung Cancer Patients

E Castellanos-Rizaldos, DG Grimm… - … : an official journal …, 2018 - pubmed.ncbi.nlm.nih.gov
Purpose: About 60% of non-small cell lung cancer (NSCLC) patients develop resistance to
targeted epidermal growth factor receptor (EGFR) inhibitor therapy through the EGFR …
Full Text @ Edgewood Coll

Exosome-Based Detection of EGFR T790M in Plasma from Non-Small Cell Lung Cancer Patients.

E Castellanos-Rizaldos, DG Grimm… - … Cancer Research: an …, 2018 - europepmc.org
Purpose: About 60% of non-small cell lung cancer (NSCLC) patients develop resistance to
targeted epidermal growth factor receptor (EGFR) inhibitor therapy through the EGFR …

Exosome-based Detection of EGFR T790M in Plasma from Non-Small Cell Lung Cancer Patients

E Castellanos-Rizaldos, DG Grimm, V Tadigotla… - scholar.archive.org
Conclusions: References: Introduction: T790M is a point mutation that arises in about 60%
of non-small cell lung cancer (NSCLC) Page 1 Contact: johan@exosomedx.com © 2017 …